Lee’s Pharma to develop Windtree drug in China; Acurx shares PhIIb antibiotic data; Granata raises $14M

Plus, news about Prota Therapeutics and Vaxart:

Windtree Therapeutics inks deal with Hong Kong group: Per the terms, Lee’s Pharmaceutical will pay Windtree up to $138.1 million to develop and commercialize its acute heart failure and cardiogenic shock treatment in Greater China. The drug istaroxime activates SERCA2a. Windtree’s stock $WINT was down about 13% on Wednesday morning. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

China biotech ban does not make the cut as add-on to defense spending bill

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 13, 2024

Agios sells vorasidenib US royalties for $905m – Pharmaceutical Technology

Caption: Royalty Pharma projects more than $1bn in annual peak sales for vorasidenib. Image credit: Shutterstock/ ADragan. As Servier’s day of reckoning with US Food

May 30, 2024

Mission Bio and University of Miami Collaborate on Multiple Myeloma Research

What You Should Know: – Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a collaboration with Dr. C. Ola Landgren, MD,

December 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.